Results 51 to 60 of about 338,947 (383)

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*

British Journal of Dermatology, 2020
Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin‐13, a key driver of atopic dermatitis (AD).
J. Silverberg, D. Toth, T. Bieber, Andrew F. Alexis, B. Elewski, A. Pink, D. Hijnen, T. N. Jensen, B. Bang, C. Olsen, A. Kurbasic, S. Weidinger   +11 more
semanticscholar   +1 more source

Inflammatory cytokines and biofilm production sustain Staphylococcus aureus outgrowth and persistence: A pivotal interplay in the pathogenesis of Atopic Dermatitis [PDF]

, 2018
Individuals with Atopic dermatitis (AD) are highly susceptible to Staphylococcus aureus colonization. However, the mechanisms driving this process as well as the impact of S. aureus in AD pathogenesis are still incompletely understood.
A Matlow, A Oliveira de, A Sandilands, A Sonesson, AC Krakowski, AD Irvine, AM Bowcock, B Cabanillas, B Han, BC Friedman, C Fux, C Pascolini, CI Ewing, CL Jinnestal, D Ellinghaus, D Lebeaux, DY Koller, DYM Leung, DYM Leung, E Clark, E Weinberg, EC Clark, EG Domenico Di, EG Domenico Di, FJ Bath-Hextall, FR Menegotto, G Stinco, GF Gad, GL Hazelbauer, GM O’Regan, GM O’Regan, GU Meduri, H Akiyama, HB Allen, HH Kong, I Marenholz, I Nomura, J Oh, J Schmitt, JH Lee, JM Hanifin, JQ Gong, K Becker, K Breuer, K Krause, KL Hon, L Chronopoulou, L Paternoster, LA O’Neill, LP Girard, M Bhattacharya, M Denis, M Mehrotra, M Niebuhr, MD Howell, ML Schuttelaar, MS Haque, P Castaneda, P Chavant, PH Hoeger, R Lever, R Saginur, RA McLaughlin, RL Gallo, RM Klevens, RP Howlin, S Eriksson, S Kanangat, S Kezic, S Kezic, S Stutte, S Weidinger, SE Hill, SE Satorres, SE Satorres, SH Cho, SH Hung, SJ Gilani, SX Xu, T Bieber, T Biedermann, T Kobayashi, T Nakatsuji, T Werfel, TX Nhan, UG Meduri, V Dossow von, W Abramovits, Z Ikezawa   +88 more
core   +1 more source

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.

New England Journal of Medicine, 2020
BACKGROUND Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis.
K. Kabashima, T. Matsumura, Hiroshi Komazaki, M. Kawashima   +3 more
semanticscholar   +1 more source

Debates in allergy medicine: Specific immunotherapy in children with atopic dermatitis, the "con" view. [PDF]

, 2016
Atopic dermatitis (AD) is a common chronic skin condition in children that has a proven association with other atopic conditions and allergies. These associations, like the general pathophysiology of AD, are complex and not fully understood.
Eichenfield, Lawrence F, Ginsberg, David N   +1 more
core   +3 more sources

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

New England Journal of Medicine, 2016
BACKGROUND Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis ...
E. Simpson, T. Bieber, E. Guttman‐Yassky, L. Beck, A. Blauvelt, M. Cork, J. Silverberg, M. Deleuran, Y. Kataoka, J. Lacour, K. Kingo, M. Worm, Y. Poulin, A. Wollenberg, Y. Soo, N. Graham, G. Pirozzi, B. Akinlade, H. Staudinger, V. Mastey, L. Eckert, A. Gadkari, N. Stahl, G. Yancopoulos, M. Ardeleanu   +24 more
semanticscholar   +1 more source

Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology [PDF]

Anais Brasileiros de Dermatologia, 2019
: BACKGROUND: Atopic dermatitis is a highly prevalent inflammatory and pruritic dermatosis with a multifactorial etiology, which includes skin barrier defects, immune dysfunction, and microbiome alterations.
Valeria Aoki, Daniel Lorenzini, Raquel Leão Orfali, Mariana Colombini Zaniboni, Zilda Najjar Prado de Oliveira, Maria Cecília Rivitti-Machado, Roberto Takaoka, Magda Blessmann Weber, Tania Cestari, Bernardo Gontijo, Andrea Machado Coelho Ramos, Claudia Marcia de Resende Silva, Silmara da Costa Pereira Cestari, Silvia Souto-Mayor, Francisca Regina Carneiro, Ana Maria Mosca de Cerqueira, Cristina Laczynski, Mario Cezar Pires   +17 more
doaj   +1 more source

Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy

Expert review of pharmacoeconomics & outcomes research, 2020
Introduction Asthma, allergic rhinitis, atopic dermatitis, and food allergy affect approximately 20% of the global population. Few studies describe the burden of the totality of these diseases and only a handful studies provide a comprehensive overview ...
B. Dierick, T. van der Molen, B. M. J. Flokstra‐de Blok, A. Muraro, M. Postma, J. Kocks, Job F. M. van Boven   +6 more
semanticscholar   +1 more source

Severe Atopic Dermatitis In Spain: A Real-Life Observational Study [PDF]

, 2019
Objective: To determine the epidemiology and characterize the treatment prescribed for severe atopic dermatitis (AD) in children/adults in usual clinical practice.
Armario Hita, José Carlos, Navarro-Artieda, Ruth, Sicras-Mainar, Antoni   +2 more
core   +2 more sources

Retrospective Study: Atopic Dermatitis in Childhood

Berkala Ilmu Kesehatan Kulit dan Kelamin (Periodical of Dermatology and Venerology), 2017
Background: Atopic dermatitis is a chronically and relapsing inflammatory skin disease affecting individuals with atopic history or their families. Atopic dermatitis affects all ageswith percentage 15-30% in children and 1-2% in adults. Chronic pruritus,
Kristina Sihaloho, Diah Mira Indramaya
doaj   +1 more source

Diagnostic Features of Atopic Dermatitis

Acta Dermato-Venereologica, 1980
is missing.
J. Hanifin, G. Rajka
semanticscholar   +1 more source